Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests

被引:2
作者
Miura, Keita [1 ]
Shukuya, Takehito [1 ]
Greenstein, Ray [2 ]
Kaplan, Ben [2 ]
Wakelee, Heather [3 ]
Kurokawa, Kana [1 ]
Furuta, Kazuyuki [4 ]
Kato, Shunsuke [5 ,6 ]
Suh, Junghee [7 ]
Sivakumar, Smruthy [2 ]
Sokol, Ethan S. [2 ]
Carbone, David P. [8 ,9 ]
Takahashi, Kazuhisa [1 ]
机构
[1] Juntendo Univ, Dept Resp Med, Grad Sch Med, 3-1-3 Hongo,Bunkyo Ku, Tokyo 1138421, Japan
[2] Fdn Med, Boston, MA USA
[3] Stanford Univ, Stanford Canc Inst, Dept Med, Div Oncol, Stanford, CA USA
[4] Chugai Pharmaceut Co Ltd, Fdn Med Business Dept, Tokyo, Japan
[5] Juntendo Univ, Fac Med, Dept Med Oncol, Tokyo, Japan
[6] Grad Sch Med, Tokyo, Japan
[7] Genentech Inc, San Francisco, CA USA
[8] Ohio State Univ, James Canc Hosp, Div Med Oncol, Comprehens Canc Ctr, Columbus, OH USA
[9] Solove Res Inst, Columbus, OH USA
来源
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2024年 / 22卷 / 07期
关键词
CELL LUNG-CANCER; MUTATIONS; DISPARITIES; FEATURES; HEALTH;
D O I
10.6004/jnccn.2024.7021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Some genomic alterations in non-small cell lung cancer (NSCLC) are known to differ according to race, sex, or age. These studies have been limited in sample size and thus they cannot detect the differences precisely and comprehensively. Methods: Tissue-based comprehensive genomic profiling was performed on 75,362 patients with NSCLC from the United States during routine clinical care. Additionally, we examined data of a Japanese NSCLC cohort with 1,019 patients. In the US cohort, 296 genes were examined for pathogenic alterations. Predominant genetic ancestry was inferred using a SNP-based approach, and patients were categorized into European (EUR), African (AFR), East Asian (EAS), Admixed American (AMR), and South Asian (SAS) ancestry groups. Patients were additionally stratified by histologic type, age (G40/>= 40 years, G75/>= 75 years), and sex. The prevalence of high tumor mutational burden (TMB-High) and microsatellite instability status was also calculated. Results: Stratified by ancestry, EGFR alterations were significantly enriched in EAS versus other ancestry groups. The prevalence of ALK was significantly higher in the AMR, EAS, and SAS patients than in AFR and EUR patients. KRAS and STK11 were enriched in EUR and AFR patients versus other groups. TMB-High was significantly enriched in AFR patients versus all other groups. An analysis based on sex revealed differences in prevalence of alterations in 80 genes and TMB-High status. For example, EGFR, ALK, BRAF, and KRAS alterations were significantly enriched in females, whereas TP53, STK11, KEAP1, and TMB-High were significantly enriched in males. With respect to age, the prevalence of alterations in 41 genes, including ALK, RET, MET, EGFR, STK11, KEAP1, BRAF, and KRAS, as well as TMB-High, were significantly different between patients aged G40 years and those aged >= 40 years. Conclusions: Comprehensive analysis from a large real-world dataset revealed ancestry-associated differences in genomic alterations in NSCLC. Age- and sex-related differences in prevalence of genomic alterations and TMB-High status were also observed. J Natl Compr Canc Netw 2024;22(7):e247021 doi:10.6004/jnccn.2024.7021
引用
收藏
页数:10
相关论文
共 42 条
  • [31] Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
    Ricciuti, Biagio
    Arbour, Kathryn C.
    Lin, Jessica J.
    Vajdi, Amir
    Vokes, Natalie
    Hong, Lingzhi
    Zhang, Jianjun
    Tolstorukov, Michael Y.
    Li, Yvonne Y.
    Spurr, Liam F.
    Cherniack, Andrew D.
    Recondo, Gonzalo
    Lamberti, Giuseppe
    Wang, Xinan
    Venkatraman, Deepti
    Alessi, Joao, V
    Vaz, Victor R.
    Rizvi, Hira
    Egger, Jacklynn
    Plodkowski, Andrew J.
    Khosrowjerdi, Sara
    Digumarthy, Subba
    Park, Hyesun
    Vaz, Nuno
    Nishino, Mizuki
    Sholl, Lynette M.
    Barbie, David
    Altan, Mehmet
    Heymach, John, V
    Skoulidis, Ferdinandos
    Gainor, Justin F.
    Hellmann, Matthew D.
    Awad, Mark M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) : 399 - 410
  • [32] Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
    Rizvi, Naiyer A.
    Hellmann, Matthew D.
    Snyder, Alexandra
    Kvistborg, Pia
    Makarov, Vladimir
    Havel, Jonathan J.
    Lee, William
    Yuan, Jianda
    Wong, Phillip
    Ho, Teresa S.
    Miller, Martin L.
    Rekhtman, Natasha
    Moreira, Andre L.
    Ibrahim, Fawzia
    Bruggeman, Cameron
    Gasmi, Billel
    Zappasodi, Roberta
    Maeda, Yuka
    Sander, Chris
    Garon, Edward B.
    Merghoub, Taha
    Wolchok, Jedd D.
    Schumacher, Ton N.
    Chan, Timothy A.
    [J]. SCIENCE, 2015, 348 (6230) : 124 - 128
  • [33] Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer
    Sadik, Helen
    Pritchard, Daryl
    Keeling, Derry-Mae
    Policht, Frank
    Riccelli, Peter
    Stone, Gretta
    Finkel, Kira
    Schreier, Jeff
    Munksted, Susanne
    [J]. JCO PRECISION ONCOLOGY, 2022, 6
  • [34] Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Eric
    Melchior, Linea C.
    Urbanska, Edyta M.
    Jakobsen, Jan N.
    de Stricker, Karin
    Grauslund, Morten
    Sorensen, Jens B.
    [J]. CANCERS, 2019, 11 (07)
  • [35] Emerging ethnic differences in lung cancer therapy
    Sekine, I.
    Yamamoto, N.
    Nishio, K.
    Saijo, N.
    [J]. BRITISH JOURNAL OF CANCER, 2008, 99 (11) : 1757 - 1762
  • [36] Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    Shigematsu, H
    Lin, L
    Takahashi, T
    Nomura, M
    Suzuki, M
    Wistuba, II
    Fong, KM
    Lee, H
    Toyooka, S
    Shimizu, N
    Fujisawa, T
    Feng, ZD
    Roth, JA
    Herz, J
    Minna, JD
    Gazdar, AF
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (05): : 339 - 346
  • [37] Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis
    Sivakumar, Smruthy
    Lee, Jessica K.
    Moore, Jay A.
    Hopkins, Julia
    Newberg, Justin Y.
    Madison, Russell
    Graf, Ryon
    Schrock, Alexa B.
    Kobetz, Erin
    Vince, Randy
    Franco, Idalid
    Seldon, Crystal
    Frampton, Garrett M.
    Mills, Jennifer
    Venstrom, Jeffrey
    Mahal, Brandon A.
    [J]. LANCET DIGITAL HEALTH, 2023, 5 (06): : E380 - E389
  • [38] STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
    Skoulidis, Ferdinandos
    Goldberg, Michael E.
    Greenawalt, Danielle M.
    Hellmann, Matthew D.
    Awad, Mark M.
    Gainor, Justin F.
    Schrock, Alexa B.
    Hartmaier, Ryan J.
    Trabucco, Sally E.
    Gay, Laurie
    Ali, Siraj M.
    Elvin, Julia A.
    Singal, Gaurav
    Ross, Jeffrey S.
    Fabrizio, David
    Szabo, Peter M.
    Chang, Han
    Sasson, Ariella
    Srinivasan, Sujaya
    Kirov, Stefan
    Szustakowski, Joseph
    Vitazka, Patrik
    Edwards, Robin
    Bufill, Jose A.
    Sharma, Neelesh
    Ou, Sai-Hong I.
    Peled, Nir
    Spigel, David R.
    Rizvi, Hira
    Aguilar, Elizabeth Jimenez
    Carter, Brett W.
    Erasmus, Jeremy
    Halpenny, Darragh F.
    Plodkowski, Andrew J.
    Long, Niamh M.
    Nishino, Mizuki
    Denning, Warren L.
    Galan-Cobo, Ana
    Hamdi, Haifa
    Hirz, Taghreed
    Tong, Pan
    Wang, Jing
    Rodriguez-Canales, Jaime
    Villalobos, Pamela A.
    Parra, Edwin R.
    Kalhor, Neda
    Sholl, Lynette M.
    Sauter, Jennifer L.
    Jungbluth, Achim A.
    Mino-Kenudson, Mari
    [J]. CANCER DISCOVERY, 2018, 8 (07) : 822 - 835
  • [39] Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma
    Soh, Junichi
    Toyooka, Shinichi
    Matsuo, Keitaro
    Yamamoto, Hiromasa
    Wistuba, Ignacio I.
    Lam, Stephen
    Fong, Kwun M.
    Gazdar, Adi F.
    Miyoshi, Shinichiro
    [J]. ONCOLOGY LETTERS, 2015, 10 (03) : 1775 - 1782
  • [40] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
    Soria, J. -C.
    Ohe, Y.
    Vansteenkiste, J.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Imamura, F.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cho, B. C.
    Cheng, Y.
    Cho, E. K.
    Voon, P. J.
    Planchard, D.
    Su, W. -C.
    Gray, J. E.
    Lee, S. -M.
    Hodge, R.
    Marotti, M.
    Rukazenkov, Y.
    Ramalingam, S. S.
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) : 113 - 125